View/ Open
Final published version (2.442Mb)
Download
Publication date
2023Rights
© 2023 The Author(s). This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.Peer-Reviewed
YesOpen Access status
openAccessAccepted for publication
2023-08-18
Metadata
Show full item recordAbstract
It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line treatment for glioma but despite the attentions of the inventors and others, further examples of this intriguing ring system have yet to enter the clinic.Version
Published versionCitation
Stevens MFG and Wheelhouse RT (2023) Antitumour Imidazotetrazines: Past, Present... and Future?. RSC Chemical Biology. 4(10): 736-741.Link to Version of Record
https://doi.org/10.1039/D3CB00076AType
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.1039/D3CB00076A